MyFinsight
Home
Blog
About
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Reimbursement right asset
Proceeds from convertible promis...
Non-cash transaction costs
Others
Negative Cash Flow Breakdown
Net loss
Prepaid expenses and other curre...
Accounts payable and accrued exp...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-6,750,127
-17,785,071
-13,443,110
-4,856,051
Depreciation
23,937
23,936
44,780
4,781
Amortization of right-of-use asset
-
-
0
0
Non-cash acquired in-process research and development cost
0
10,426,257
-
-
Non-cash transaction costs
280,000
-
6,836,992
-
Share-based compensation expense
-
-
61,865
134,324
Change in fair value of contingent consideration
217,000
-116,000
-1,584,000
-
Change in fair value of warrant liabilities
-229,221
125,348
-398,476
279,161
Due from related parties
-
-
638
-
Pipe warrant issuance cost
9,534
-
-
-
Prepaid expenses and other current assets
644,024
695,656
-911,823
1,026,051
Accounts payable and accrued expenses
-585,951
1,774,088
-43,150
1,402,837
Deferred grant income
-21,315
85,262
0
0
Grant receivable
0
-952,460
754,164
22,174
Security deposit
-
-
0
0
Operating lease liability
-
-
0
0
Reimbursement right asset
-2,297,806
-
-
-
Deferred tax liability
300
231,309
226,068
-
Net cash used in operating activities
-5,402,061
-4,978,067
-8,142,010
-4,083,173
Cash acquired through the acquisition of polynoma
-
-
2,224
-
Purchase of equipment
-
-
6,660
-
Net cash used in investing activities
-
-
-4,436
-
Proceeds from offering of preferred stock (series b), net of offering costs
-
-
22,668,324
-
Net proceeds from sales of common stock
-
-
1
0
Payments of deferred offering costs
-
-
-
455,726
Proceeds from convertible promissory notes
950,000
-
-
-
Net cash provided by financing activities
950,000
-
23,124,051
-455,726
Net change in cash
-4,452,061
-4,978,067
14,977,605
-4,538,899
Cash, beginning of period
12,835,454
17,813,521
2,835,916
5,811,064
Cash, end of period
8,383,393
12,835,454
17,813,521
2,835,916
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from
convertible promissory...
$950,000
Net cash provided by
financing activities
$950,000
(-89.27%↓ Y/Y)
Net change in cash
-$4,452,061
(-384.70%↓ Y/Y)
Canceled cashflow
$950,000
Reimbursement right asset
-$2,297,806
Non-cash transaction
costs
$280,000
Change in fair value of
contingent consideration
$217,000
Depreciation
$23,937
(-10.97%↓ Y/Y)
Pipe warrant
issuance cost
$9,534
Deferred tax liability
$300
Net cash used in
operating activities
-$5,402,061
(25.91%↑ Y/Y)
Canceled cashflow
$2,828,577
Net loss
-$6,750,127
(58.74%↑ Y/Y)
Prepaid expenses and
other current assets
$644,024
(208.88%↑ Y/Y)
Accounts payable and
accrued expenses
-$585,951
(48.74%↑ Y/Y)
Change in fair value of
warrant liabilities
-$229,221
(-102.44%↓ Y/Y)
Deferred grant income
-$21,315
(16.11%↑ Y/Y)
Buy us a coffee